ArticleJournal of oral microbiology2026
Association between the oral microbiome and clinical indicators of resectable non-small cell lung cancer (NSCLC).
Article in Journal of oral microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The oral-lung axis in lung cancer: microbial translocation, immune reprogramming, and clinical implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral microbial implications for lung cancer outcomes and association with clinical markers are largely unknown. Objective: This work aimed to characterize the oral microbiome in relation to clinical indicators and identify oral microbial biomarkers associated with lung cancer outcomes in patients with non-small cell lung cancer (NSCLC). Design: This is an observational prospective study of saliva samples from patients undergoing curative surgery for NSCLC. Taxonomic and composition profiles were generated using full-length 16S rRNA gene sequencing (n=64). Differences in bacterial diversity and composition with cancer stage, histological subtype, overall survival (OS), and event-free survival (EFS) were examined. Results: Most alpha diversity measures were lower with stage III cancer compared to stage I. All other clinical features were not statistically associated with alpha diversity (P>0.05). The relative abundance of Haemophilus and Solobacterium was detected as significantly differentially abundant in participants with stage III NSCLC by at least 2 differentially abundant tools and an FDR-corrected p-value<0.1. Conclusion: This study shows a significant association between cancer stage with oral bacterial diversity and the relative abundance of specific genera in relation to OS in participants with resectable NSCLC. This study is limited by sample size and needs to be confirmed in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.